论文部分内容阅读
目的观察孟鲁司特钠联合红霉素、阿奇霉素治疗小儿肺炎支原体肺炎(MPP)的临床疗效。方法将MPP患儿60例按照数字表法随机分为观察组和对照组,每组30例;对照组在常规治疗基础上给予红霉素静脉滴注、口服阿奇霉素治疗,观察组在对照组基础上联合使用孟鲁司特钠治疗。比较2组患者的临床疗效、退热时间、啰音消失时间、咳嗽消失时间、喘息消失时间和住院时间,血清C反应蛋白(CRP)水平及药物安全性。结果观察组总有效率为93.3%高于对照组的83.3%,差异有统计学意义(P<0.05)。观察组退热时间,啰音、咳嗽、喘息消失时间和住院时间均短于对照组,差异有统计学意义(P<0.05)。治疗前,2组CRP水平比较差异无统计学意义(P>0.05)。治疗后,2组CRP水平均降低,且观察组低于对照组,差异均有统计学意义(P<0.05)。对照组患者出现不良反应6例,其中恶心3例、头晕1例、腹泻2例;观察组出现不良反应7例,其中恶心3例、腹痛1例、腹泻3例,2组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论孟鲁司特钠联合红霉素、阿奇霉素治疗小儿MPP疗效确切,能快速缓解患者临床症状和体征,安全性好,值得临床推广应用。
Objective To observe the clinical efficacy of montelukast sodium combined with erythromycin and azithromycin in the treatment of children with Mycoplasma pneumoniae pneumonia (MPP). Methods Sixty children with MPP were randomly divided into observation group and control group according to the digital table method, with 30 cases in each group. The control group received erythromycin intravenous drip and oral azithromycin on the basis of routine treatment. The observation group was basal in control group On the combined use of montelukast sodium treatment. Clinical efficacy, antipyretic time, rales disappearance time, cough disappearance time, wheezing disappearance time and hospital stay, serum C-reactive protein (CRP) level and drug safety were compared between the two groups. Results The total effective rate in observation group was 93.3%, which was significantly higher than that in control group (83.3%) (P <0.05). The observation group antipyretic time, rales, cough, asthma disappear time and hospitalization time were shorter than the control group, the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in CRP level between the two groups (P> 0.05). After treatment, CRP levels in both groups decreased, and the observation group was lower than the control group, the difference was statistically significant (P <0.05). There were 6 adverse reactions in the control group, including 3 cases of nausea, 1 case of dizziness and 2 cases of diarrhea. There were 7 cases of adverse reactions in the observation group, including 3 cases of nausea, 1 case of abdominal pain, 3 cases of diarrhea and 2 cases of adverse reactions The difference was not statistically significant (P> 0.05). Conclusion Montelukast sodium combined with erythromycin and azithromycin in children with MPP is effective and can quickly relieve the clinical symptoms and signs of patients with good safety and is worthy of clinical application.